ORIC PHARMACEUTICALS, INC. Shareholders' Equity
ORIC PHARMACEUTICALS, INC. (ORIC) had Shareholders' Equity of $381.26 million as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-03
- 2026-06-30: Stockholders' Equity Attributable to Parent $381.26M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $415.56M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $384.36M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $406.92M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $381.26M 10-Q · filed 2026-08-03 |
| 2026-03-31 | $415.56M 10-Q · filed 2026-08-03 |
| 2025-12-31 | $384.36M 10-Q · filed 2026-08-03 |
| 2025-09-30 | $406.92M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $324.00M 10-Q · filed 2026-08-03 |
| 2025-03-31 | $219.74M 10-Q · filed 2026-08-03 |
| 2024-12-31 | $243.12M 10-Q · filed 2026-08-03 |
| 2024-09-30 | $273.99M 10-Q · filed 2025-11-13 |
| 2024-06-30 | $302.40M 10-Q · filed 2025-11-13 |
| 2024-03-31 | $328.64M 10-Q · filed 2025-11-13 |
| 2023-12-31 | $224.09M 10-K · filed 2026-02-23 |
| 2023-09-30 | $247.41M 10-Q · filed 2024-11-12 |
| 2023-06-30 | $268.80M 10-Q · filed 2024-11-12 |
| 2023-03-31 | $202.81M 10-Q · filed 2024-11-12 |
| 2022-12-31 | $222.35M 10-K · filed 2025-02-18 |
| 2022-09-30 | $214.82M 10-Q · filed 2023-11-06 |
| 2022-06-30 | $236.87M 10-Q · filed 2023-11-06 |
| 2022-03-31 | $253.08M 10-Q · filed 2023-11-06 |
| 2021-12-31 | $272.98M 10-K · filed 2024-03-11 |
| 2021-09-30 | $291.54M 10-Q · filed 2022-11-07 |
| 2021-06-30 | $258.32M 10-Q · filed 2022-11-07 |
| 2021-03-31 | $276.07M 10-Q · filed 2022-11-07 |
| 2020-12-31 | $289.78M 10-K · filed 2023-03-16 |
| 2020-09-30 | $184.38M 10-Q · filed 2021-11-08 |
| 2020-06-30 | $195.25M 10-Q · filed 2021-11-08 |
| 2020-03-31 | -$98.42M 10-Q · filed 2021-11-08 |
| 2019-12-31 | -$90.08M 10-K · filed 2022-03-21 |
| 2019-09-30 | -$82.21M 10-Q · filed 2020-11-05 |
| 2019-06-30 | -$75.94M 10-Q · filed 2020-11-05 |
| 2019-03-31 | -$70.23M 10-Q · filed 2020-11-05 |
| 2018-12-31 | -$64.43M 10-K · filed 2022-03-21 |
| 2017-12-31 | -$43.61M 10-K · filed 2021-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |